Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 ( NPM1 ) mutation or Fms‐like tyrosine kinase 3 internal tandem duplication ( FLT3‐ ITD)

Summary About 25% of patients with newly diagnosed acute myeloid leukaemia (AML) have normal cytogenetics and no nucleophosmin 1 ( NPM1 ) mutation or Fms‐like tyrosine kinase 3 internal tandem duplication ( FLT3‐ ITD). The prognosis and best therapy for these patients is controversial. We evaluated 158 newly diagnosed adults with this genotype who achieved histological complete remission within two cycles of induction therapy and were assigned...